Louisa Stone
Manager of Investor Relations, Viridian Therapeutics
Replay available
Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call
Viridian Therapeutics, Inc. (NASDAQ: VRDN) Q1 2024 earnings conference call, held 2024-05-08. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Steve Mahoney
President and Chief Executive Officer, Viridian Therapeutics
Tom Shula
Chief Medical Officer, Viridian Therapeutics
Laura Chico
Analyst, Wedbush Securities
Alex Thompson
Analyst, Stifel
Michael Yee
Analyst, Jefferies
Gavin Clark-Gartner
Analyst, Evercore ISI
Rainey Kakuda
Analyst, LifeSci Capital
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Viridian Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:01.330 -- 00:00:05.694 Later, we will conduct a question and answer session and instructions will be given at 00:00:05.694 -- 00:00:09.998 that time. As a reminder, this conference call is being recorded. 00:00:09.998 -- 00:00:12.940 I would now like to hand the call over to Ms. 00:00:12.940 -- 00:00:16.863 Louisa Stone, Manager of Investor Relations at Viridian. 00:00:16.863 -- 00:00:18.905 Please go ahead. 00:00:18.905 -- 00:00:23.449 Thank you and welcome everyone to our first quarter 2024 00:00:23.449 -- 00:00:28.146 earnings conference call. The press release reporting our financial results and corporate 00:00:28.146 -- 00:00:34.589 updates is available on the investors' page of our corporate website at www.viridiantherapeutics.com. 00:00:36.973 -- 00:00:42.117 Joining me on the call this morning are Steve Mahoney, our President and CEO, Tom 00:00:42.117 -- 00:00:48.362 Shula, our Chief Medical Officer, and Sean Wu, our Chief Business Officer. 00:00:48.362 -- 00:00:52.966 Before we begin, I would like to remind everyone that this conference call and webcast 00:00:52.966 -- 00:00:57.790 will contain forward-looking statements regarding our financial outlook, in addition 00:00:57.790 -- 00:01:03.355 to regulatory product development and commercialization plans and research activities. 00:01:03.355 -- 00:01:07.959 These statements are subject to risks and uncertainties that could cause actual results 00:01:07.959 -- 00:01:11.454 to materially differ from those forecasted. 00:01:11.454 -- 00:01:17.337 A description of these risks can be found in our most recent form 10Q and 10K 00:01:17.337 -- 00:01:22.359 on file with the SEC. I would now like to turn the call over to Steve Mahoney, our 00:01:22.359 -- 00:01:25.019 President and CEO. 00:01:25.481 -- 00...